Modality
Vaccine
MOA
Menini
Target
Aβ
Pathway
PI3K/AKT
Ewing SarcomaRSVCLL
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
→ May 2029
Phase 2Current
NCT05048804
1,385 pts·Ewing Sarcoma
2019-08→2026-06·Terminated
NCT04747170
1,009 pts·Ewing Sarcoma
2023-04→2029-05·Recruiting
2,394 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-082mo awayPh2 Data· Ewing Sarcoma
2029-05-143.1y awayPh2 Data· Ewing Sarcoma
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2026-06-08 · 2mo away
Ewing Sarcoma
Ph2 Data
2029-05-14 · 3.1y away
Ewing Sarcoma
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05048804 | Phase 2 | Ewing Sarcoma | Terminated | 1385 | PASI75 |
| NCT04747170 | Phase 2 | Ewing Sarcoma | Recruiting | 1009 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| ARG-314 | Argenx | Approved | Aβ |